Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Savara Inc.
< Previous
1
2
Next >
Savara Announces New Employment Inducement Grant
November 22, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
November 22, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces Participation in Upcoming Healthcare Conferences
November 13, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
November 04, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
October 22, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces New Employment Inducement Grant
October 18, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
October 01, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces New Employment Inducement Grant
September 27, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
September 27, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
September 24, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Host Analyst and Investor Webinar on September 30, 2024
September 23, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
September 08, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces New Employment Inducement Grant
September 06, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces New Employment Inducement Grant
August 16, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
August 15, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
June 28, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
June 26, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
June 25, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
May 19, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces New Employment Inducement Grant
May 16, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Present at the Citizens JMP Life Sciences Conference
May 07, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
April 08, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Announces New Employment Inducement Grant
March 22, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
March 07, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024
From
Savara Inc.
Via
Business Wire
Tickers
SVRA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.